Invesco
VIRX

Invesco’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Invesco’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,377
Closed -$54K – 4170
2022
Q1 		$54K Buy
11,377
+42
+0.4% +$127 ﹤0.01% 3925
2021
Q4 		$41K Sell
11,335
-400
-3% -$2.13K ﹤0.01% 3997
2021
Q3 		$94K Buy
+11,735
New +$116K ﹤0.01% 3949
2013
Q3 		– Sell
-93
Closed -$101K – 4345
2013
Q2 		$101K Buy
+93
New +$104K ﹤0.01% 3943

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Invesco's VIRX Position: Q2 2022 in Review

Invesco sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2022, closing a stake of 11,377 shares — an estimated $54K sold.

Invesco first reported a position in VIRX in Q2 2013 and held it in 4 quarters. The position peaked at $101K in Q2 2013. 63 funds tracked by Wall St. Rank hold VIRX as of Q2 2022.

  • Invesco reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Invesco sold 11,377 Viracta Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $54K.
  • Invesco first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 4 quarters.
  • Invesco's Viracta Therapeutics, Inc. Common Stock position peaked at $101K in Q2 2013.
  • 63 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Invesco's 13F filing for Q2 2022, filed 15 Aug 2022.